

TABLE 3 - SUMMARY OF 12-Month ACCRUAL SEPARATED OUT BY MONTH AND BY COMPONENT/AFFILIATE

PARTICIPANT ACCRUAL SUMMARY - June 1, 2003 through May 31, 2004

1. Indicate total number of new participants (not credit equivalents) entered on NCI- approved treatment and cancer prevention and control studies by month.

<u>Month</u>	<u>Number of New Participants</u>	
	<u>Treatment</u>	<u>Cancer Prevention and Control</u>
June 2003		
July		
August		
September		
October		
November		
December		
January 2004		
February		
March		
April		
May		
	Total:	

2. Indicate total number of participants (not credit equivalents) entered on NCI approved treatment and cancer prevention and control studies by each component or affiliate.

<u>Name of Component/Affiliate*</u>	<u>Number of New Participants</u>	
	<u>Treatment</u>	<u>Cancer Prevention and Control</u>
	Total:	

Table 4 - CCOP/MBCOP PARTICIPANT REPRESENTATION BY SEX AND ETHNIC ORIGIN
SEX AND ETHNIC ORIGIN - June 1, 2003 through May 31, 2004

Please list each NCI-approved protocol on which you have entered participants. Provide one line for each protocol. Additional lines should be included for protocols receiving more than one type of credit. Include:

- (1) NCI protocol number (Alphanumeric)
- (2) Sex (M=Male, F=Female, U=Unknown)
- (3) Type of Credit (RX=Treatment, CC=Cancer Prevention and Control)
- (4) Ethnicity (H=Hispanic, N=Not-Hispanic, U=Unknown)

(5)-(11) Ethnic Origin - Enter the number of participants for each ethnic origin. (See page 10 of the PHS 2590 for definitions.)

(1) Protocol Number	(2) Sex	(3) Type of Credit	(4) Ethnicity: Hispanic or Not-Hispanic or Unknown	(5) American Indian or Alaskan Native	(6) Asian	(7) Native Hawaiian or Pacific Islander	(8) Black	(9) White	(10) More than One Race	(11) Other or Unknown
Examples: EST-E5Y92	F	RX	N	1	0	2	3	2	3	0
CALGB-9170	M	CC	N	0	1	3	0	0	2	0
CALGB-9170	M	CC	H	0	0	1	1	3	1	1
CALGB-9997	M	RX	H	0	1	0	2	1	0	2

Please do not include follow-up participants. Do not enter registered or run-in participants for any protocol. Count only participants randomized on protocols.